Artificial receptors

1. An isolated antibody comprising an antigen binding domain which comprises complementarity determining regions (CDRs) as set forth by SEQ ID NOs:99-101 for CDRs 1-3, respectively of the heavy chain, and SEQ SEQ ID NOs: 102-104 for CDRs 1-3, respectively of the light chain.

2. A system for controllable delivery of a molecule-of-interest to a tissue comprising:

(i) the molecule-of-interest conjugated to the antibody of claim 1 , and;

(ii) an artificial receptor which comprises a surface having an extent, said surface comprises a hydroquinone and a switching functionality for controllably modifying electrical properties of said surface, wherein said antigen binding domain of said antibody is capable of binding said hydroquinone, and wherein said switching functionality controls a binding or a release of said antibody from said hydroquinone.

3. The system of claim 2 , configured for implantation in a subject in need thereof.

4. A method of controlling a delivery of a molecule-of-interest to a tissue of a subject, comprising:

(a) contacting the system of claim 2 with the tissue of the subject, and;

(b) modifying said electrical properties of said surface to thereby control a binding or a release of said antibody from said artificial receptor;

thereby controlling the delivery of the molecule-of-interest to the tissue.

5. The method of claim 4 , wherein the molecule-of-interest is selected from the group consisting of a drug, a toxin and a detectable moiety.

6. The method of claim 4 , wherein said modifying said electrical properties of said surface is effected using a remote switching unit.

7. The method of claim 4 , wherein said hydroquinone comprises a hydroquinone monolayer.

8. The method of claim 4 , wherein said surface further comprises gold, and whereas said hydroquinone is attached to said surface by conjugating to said gold.

9. The method of claim 4 , wherein modification of said electrical properties of said surface results in a conformation change of said hydroquinone to a benzoquinone and whereas said antibody is incapable of binding said surface following said modification.

10. The method of claim 4 , wherein said switching functionality is obtained by carbon nanotubes and/or silicone nanowires.

11. The method of claim 4 , wherein said artificial receptor further comprises a laminate including a plurality of independently electrifiable layers, said surface being formed from a cross-section of said laminate.

12. The method of claim 11 , wherein said switching functionality comprises a selector for selecting a voltage level for each of said independently electrifiable layers, to thereby allow change in an electrical field of said surface.

13. A system comprising:

(i) the antibody of claim 1 , and;

(ii) a surface comprising hydroquinone;

wherein the antibody is capable of binding said hydroquinone.